Silence Therapeutics has announced the appointment of Dmitry Samarsky as Chief Scientific Officer (CSO) and Dr Andy Richards CBE (pictured) as Non-Executive Director and member of the Board.
Dmitry brings a strong track record in the discovery and development of RNA therapeutics. Widely recognised as an expert in the oligonucleotide field, he joins the Company from OliX Pharmaceuticals where he held the position as Senior VP of Technology and Global Business Development. Previously, as Senior VP of Technology and International Business Development at RiboBio (China), Dmitry played a pivotal role in placing the company amongst the international players in the oligonucleotide field between 2011 and 2015.
Andy is a specialist entrepreneur and investor in the biotechnology sector. He is currently Chairman of several UK biotechnology companies, including IXICO, Abcodia, Congenica and Babraham Bioscience Technologies. He is also a director of Cancer Research Technology, IESO Digital Health and Cambridge University Hospitals NHS Foundation Trust.
